Biomarkers Identify Immune Checkpoint Inhibitor-Related Acute Kidney Injury
Prompt diagnosis of AKI and the ability to rule out immune checkpoint inhibitors as the cause may allow patients to continue with cancer immunotherapy.
Immunotherapy
Modified Nivolumab-Ipilimumab Dosing Shows No Benefit in Advanced RCC
A modified dosing regimen of nivolumab-ipilimumab for patients with advanced RCC did not provide additional benefit compared with standard dosing.
-
Loading...
-
Loading...
Next post in Kidney Cancer
